Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Effect on Atherosclerosis in T2D and CVD
NCT04032197Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in atherosclerosis and type 2 diabetes mellitus (T2DM) comparing Semaglutide Arm with Placebo Arm (2 arms). Primary endpoint: Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries at 26 weeks. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
atherosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04032197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032197.